Abstract 33P
Background
Evidence highlights the critical role of CD4 T cells in antitumor immunity and immunotherapy. We previously reported that baseline or post-treatment hTERT-specific CD4 Th1 response in blood is associated with the efficacy of immune checkpoint inhibitors (ICI) therapy in patients with advanced melanoma and colorectal cancer (Nardin et al, 2021; Thibaudin et al, 2022). Here, we investigated the involvement of peripheral tumor reactive CD4 Th1 response in durable response to ICI in melanoma patients.
Methods
Blood samples were collected in three groups of advanced melanoma (AJCC8 stage III/IV) patients (pts) according to response to ICI: 50 pts with prolonged disease control (>1 year) (CD[FA1]), 22 pts with primary resistance (R1) defined as no response after 3 months of ICI, and 35 pts with relapsed disease after treatment discontinuation for initial disease control (>1 year) (R2). Multiparametric immunologic analyses were performed using IFN-γ ELISpot, flow cytometry on PBMC and Bulk RNA sequencing on circulating sorted CD4 T cells.
Results
A high frequency of circulating tumor-specific CD4 Th1 response, i.e response against at least one of the 3 antigens tested (hTERT, MAGE-A3 and KK-LC1), was found in all 3 groups (76%, 63%, 68% in CD, R1, R2, respectively). Among the 3 antigens tested, the circulating hTERT-specific CD4 Th1 response frequency was higher in CD compared to R1 and R2 : 70% vs 25% vs 40% positive response (**, p<0.01). Furthermore, CD4 Th1 polyspecific responses, i.e against at least 2 of the 3 antigens tested were more detected in CD pts (31 pts, 62%) compared to 15 (42%) and 7 (32%) pts in R2 and R1 respectively. hTERT-specific CD4 Th1 exhibits cytotoxic phenotype and a modified memory profile compared to non-specific CD4 T cells. Transcriptomic analyses of CD4 T cells revealed 669 genes upregulated and 52 down-regulated in CD pts, mainly enriched in Th1-associated pathways such as IFN-γ response, TNF-α signaling via NF-κB and IL-2-STAT5 signaling compared to healthy donors. Analyses of immune-related genes showed upregulation of cytotoxic markers in CD pts compared to R1 and R2.
Conclusions
In conclusion, our data demonstrated that cytotoxic hTERT-specific CD4 Th1 response is involved in the long-term response to ICI.
Legal entity responsible for the study
CHRU Besançon.
Funding
La ligue contre le cancer; Bourse Chrysalide.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract